series-b
Stage
About
LinqMed, Inc develops next-generation radiopharmaceutical drugs utilizing the copper radioisotope 64Cu for the diagnosis and treatment of intractable cancers, including innovative visible anti-cancer therapies.
Explore LinqMed, Inc's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.